Abstract Over the past decade, treatment options for patients with multiple myeloma (MM) have improved substantially, resulting in better response rates and prolonged overall survival (OS). Nevertheless, MM remains a challenging disease, especially if renal insufficiency (RI) or extensive pretreatment aggravates the assignment of the optimal treatment schedule. In this retrospective study, we analyzed the outcome of lenalidomide plus dexamethasone in 167 patients with relapsed or refractory MM with focus on RI. The baseline creatinine clearance (CL Cr ) was normal in 94 patients (CL Cr ≥ 80 ml/min), while RI was observed in 73 patients, including 40 patients with mild RI (50≤CL Cr <80 ml/min) and 33 patients with moderate or severe RI (CL Cr <50 ml/min). Response rates declined depending on the severity of RI, being 67% among patients with normal kidney function, 60% among patients with mild RI and 49% among patients with moderate or severe RI. Time to progression (TTP) was significantly reduced in patients with severe RI and in case of >2 previous treatment lines. OS was not significantly different between patients with normal and impaired renal function. In contrast, the number of previous treatment lines (2 vs. <2) and the use of novel agents like bortezomib or thalidomide prior to lenalidomide plus dexamethasone therapy had a more adverse effect on OS. In conclusion, lenalidomide plus dexamethasone is an effective regimen for relapsed or refractory patients with MM complicated by RI with manageable toxicity.
Introduction
Considerable effort has been put into understanding the pathomechanism of multiple myeloma (MM), optimizing diagnostic procedures and therapeutic strategies, leading to substantial advances in treatment options and survival duration in the past decade, mostly due to new therapeutic agents [1] . However, MM remains a challenging hematological neoplasm. Lenalidomide is an agent with proven efficacy and tolerability in relapsed and newly diagnosed patients. Its targets are not only the MM cell, but also cell-host interactions, cytokine-secretion and the BM milieu [2] . Management of MM patients is often complicated by the fact that up to 20 to 40% of patients suffer from renal insufficiency (RI) [3] [4] [5] [6] [7] . The main reason for this is the accumulation and precipitation of light chains forming casts, resulting in renal tubules obstruction. They also seem to alter renal function by direct toxic effects on the proximal renal tubules; hypercalcaemia and dehydratation, with nephrotoxic medication enhancing this renal damage [8] [9] [10] [11] . Advanced age of MM patients can also be a cofactor for RI, as it might be associated with an increased incidence of cardiovascular or endocrine disorders. Data from retrospective analyses and sub-analyses of prospective trials for conventional chemotherapy reveal that TTP and OS are reduced in patients with RI [12] [13] [14] . Therefore, effective treatment modalities having no or little renal toxicity and the potential ability to improve renal impairment are preferred. In the literature, bortezomib has been identified to be the best choice for these patients, particularly as no dose adjustment is needed for any degree of RI and response and improvement of renal function take place rapidly [15] . In case of impaired renal function, therapy with lenalidomide requires adjustment to be feasible. Oral absorption, protein binding, or non-renal elimination of lenalidomide are not altered by RI. However, renal clearance of lenalidomide decreases drastically in patients with severe renal dysfunction, whereas drug exposure and half-life time are increased. Therefore, dose adjustments are recommended for patients with a creatinine clearance CL Cr of less than 50 ml/ min [16] . Prospective data from clinical trials on the application of lenalidomide in patients with MM and renal impairment, however, are not available.
As data from randomized studies are lacking, the question of when to best apply salvage therapy in relapsed or refractory disease remains to be discussed as controversially as the correct implementation of new therapeutic agents, particularly since these agents took place in various upfront strategies. It is well known that the probability of treatment response decreases with increasing numbers of previous therapies [17] . In addition, the time to progression (TTP) is abbreviated with each salvage therapy applied.
The current investigation is a retrospective analysis to evaluate the influence of renal impairment and previous therapies in patients with relapsed MM who have been treated with lenalidomide at a single centre.
Patients and methods
Between July 2005 and June 2009, 167 patients with refractory or relapsed MM were treated at our centre with a combination of lenalidomide plus dexamethasone. Treatment consisted of lenalidomide (25 mg on days 1 to 21) and dexamethasone (cycle duration 28 days) according to the two phase III studies, which led to the approval of lenalidomide in relapsed and refractory MM patients [18, 19] . The first 13 patients (7.8%) received high-dose dexamethasone with 40 mg on days 1-4, 9-12 and 17-20, but due to severe infectious complications we decided in our centre to reduce the dosage for all patients about 50% to 20 mg days 1-4, 9-12 and 17-20. A total of 132 patients (79.0%) received this schema. With the emerging data of the low-dose dexamethasone schedule of Rajkumar et al., 12 patients (7.2%) received the reduced dosage of dexamethasone according to the Eastern Cooperative Oncology Group (ECOG) E4A03 study with 40 mg on days 1, 8, 15 and 22 because of expected severe side effects of dexamethasone due to their personal risk profile [20] . Of the 20 patients who received lenalidomide plus dexamethasone after allogenic transplantation and due to the concomitant immunosuppressive therapy, eight patients (4.8%) got a further reduced dexamethasone dosage (two patients, 0 mg dexamethasone; four patients, 80 mg per cycle; one patient, 96 mg per cycle; one patient 144 mg per cycle). The remaining two patients received 80 and 120 mg per cycle respectively as an individualized treatment decision.
Dose adjustments for patients with RI were made in case of a baseline CL cr ≤50 ml/min or worse. Patients with a moderate RI (30≤CL Cr ≤50 ml/min) received 10 mg lenalidomide daily; patients with a severe RI (CL Cr <30 ml/min) received 15 mg every other day, whereby patients requiring dialysis received lenalidomide 15 mg after dialysis. However, 11 patients with moderate RI received-due to their borderline CL Cr and the fact that their serum creatinine was below 1.7 mg/dl-the full dosage with 25 mg lenalidomide on days 1-21. One patient with a baseline CL Cr of 25 ml/min received 25 mg lenalidomide as well, because serum creatinine was normal and collected volume of urine was only 1.200 ml/24 h. Treatment was administered until disease progression or unacceptable toxicity occurred. Lenalidomide and dexamethasone were administered as re-induction therapy in 41 patients, followed by high dose chemotherapy and autologous stem cell transplantation (ABSCT). At the time of this analysis, 40 patients have undergone ABSCT. In the statistical analysis ABSCT was computed as a competing risk. For the analysis of RI, patients were classified into the following RI subgroups based on their baseline cratinine clearance (CL cr ) as determined in a 24-h urine sample: no RI CL Cr >80 ml/min, mild RI 50≤ CL Cr ≤80 ml/min, moderate RI 30≤CL Cr ≤50 ml/min or severe RI CL Cr <30 ml/min. As the dosage of lenalidomide is linked to the classification of the Glomerular filtration rate (GFR) (80-50 ml/min, 50-30 ml/min, <30 ml/min without dialysis and dialysis dependency), we decided to classify the patients as well in these categories, even if nephrologists consider normal renal function as GFR >90 ml/min. Information on CL Cr at the time of treatment initiation was available for 165 patients (98.8%). For two patients, CL Cr at the start of therapy was not available; therefore the MDRD (modification of diet in renal disease) formula was used instead. Both patients had in previous measurements always normal CL Cr and at the time of beginning normal values for creatinine and urea, so they were counted as normal kidney function. Due to the relatively small number of patients with moderate to severe RI, these groups were combined for the statistical analysis. The numbers of pre-treatment were recorded for all patients. Every treatment schedule which was necessitative due to relapse or refractory disease was counted as one therapy. Induction, mobilization, autologous transplantation and maintenance therapy were counted as one therapy. Response to treatment was assessed according to the European Group for Blood and Marrow Transplantation criteria for complete remission (CR), partial response (PR), minimal response (MR), stable disease (SD) and progressive disease [21] . The criteria were complemented by the criteria of the International Myeloma Working Group for very good partial response (VGPR) and near complete remission (nCR) [22] . CR was defined as no M-protein detectable by electrophoresis and immunofixation in the serum and urine, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in the bone marrow. nCR was defined as complete disappearance of the monoclonal protein, except for a positive immunofixation. VGPR was defined as at least 90% reduction in serum M-protein and urine M-protein level below 100 mg/24 h. PR was defined as at least 50% reduction of serum M-protein and reduction in 24-h urinary sample Mprotein by at least 90% or less than 200 mg/24 h. MR was defined as a 25% to 49% reduction in serum M-protein and reduction in 24-h urinary sample M-protein by 50% to 89%. Progressive disease was defined by any of the following: an increase of at least 25% from baseline serum or urinary Mprotein, equalling at least an absolute increase of at least 500 mg/dl in serum or 200 mg/24 h in urine; newly occurred or increased size of bone lesions or soft-tissue plasmacytomas, or development of hypercalcaemia. Efficacy was measured by overall response rate (ORR), which is defined as CR + VGPR + PR rate. ORR was assessed as best response during treatment with lenalidomide plus dexamethasone. TTP was evaluated as time from start of lenalidomide plus dexamethasone to first assessment of disease progression. Patients without evidence of progression were censored at their last information. Overall survival (OS) was defined as start of lenalidomide plus dexamethasone until death from any cause or last follow-up visit, whichever occurred first. Follow-up data on OS were obtained up to June 2009, for a median follow-up duration of 15.7 months. The review board of our institution approved of the retrospective analysis and patients provided written informed consent.
Statistical analysis
Estimation of OS distribution was performed by the method of Kaplan and Meier. For comparisons of OS curves, the log-rank test was used. In addition, Cox PH regression analysis was used to evaluate the prognostic impact in a univariate model as well as in a multivariate model together with prognostically relevant clinical factors. TTP was evaluated in a competing risk analysis with ABSCT being the competing risk. TTP was analysed fitting a subdistributional hazard regression model [32] . This model directly assesses the effect of a prognostic factor on TTP in a competing risk setting and allows incorporating additional covariates. TTP distribution was estimated using cumulative incidence rates. Post-baseline factors were included as time-dependent covariates. Response rates were compared with Fisher's exact test. The result of a test was always judged as statistically significant when the corresponding two-sided p value was below 0.05. The prognostic value of clinical factors was assessed by their estimated hazard ratios including 95% confidence intervals. All statistical computations were performed with the statistical software environment R, version 2.9.0 (R Development Core Team, 2009) using the R package cmprsk version 2.2-0 using the R add-on packages cmprsk and kmi [33] .
A propensity score analysis was performed to account for imbalances at baseline between patients with severe and without renal impairment, adjusting for age, sex, number of previous therapies, previous treatment with bortezomib, thalidomide or both, time between start of first-line treatment and start of lenalidomide, and time between last MM treatment and start of lenalidomide. Adjusted Kaplan-Meier curves for OS were computed using the propensity scores in an inverse probability weighting scheme [23] .
Results

Patients
From July 2005 to June 2009, 167 patients with relapsed or refractory MM were treated with lenalidomide plus dexamethasone in our centre, forming the base of this analysis. Normal renal function with no RI (CL Cr ≥80 ml/min) was observed in 94 patients, 40 (23.9%) patients had mild RI (50≤CL Cr <80 ml/min), 21 (12.6%) had moderate (30≤ CL Cr <50 ml/min) and 12 patients (7.2%) had severe RI (CL Cr <30 ml/min), of whom five patients (3%) required hemodialysis. Further baseline characteristics are presented in Table 1 . When compared to patients without RI, patients with RI were more likely to be female and patients with normal renal function were more likely to have a lower median number of previous therapies (two vs. three in mild RI and three in severe RI) and are less likely to have received bortezomib and/or thalidomide prior to lenalidomide plus dexamethasone when compared to patients with mild or severe RI (22.3% vs. 45.0% vs. 36.4%).
Efficacy
In the entire group, the ORR (≥PR) was 61.7%, while the CR rate was 11.4%. Overall response rates and CR rates declined depending on the severity of renal impairment, being 67.0% among patients with normal kidney function (CR 14.9%), 60.0% among patients with mild RI (CR 10.0%) and 48.5% among patients with moderate or severe RI (CR 3.0%) (ORR adj. p value=0.66). Efficacy was also strongly influenced by the type of pre-treatment and the occurrence of relapse from remission or primary refractory disease. A detailed description is listed in Table 2 .
Time to progression TTP was defined as time from start of lenalidomide plus dexamethasone therapy until disease progression. During the follow-up of 15.7 months, a total of 101 events occurred. The median TTP based on the cumulative incidence function for the overall population is 9.02 months. TTP is significantly shortened in case of mild RI (p=0.007) and ≥moderate RI (p=0.005) vs. no renal impairment (Fig. 2a) . In order to identify the effect of more intense pre-treatment in patients with renal impairment, we performed a multivariate analysis. The following parameters were considered in addition to kidney function and previous treatment schedules within a multivariate Cox PH model: age, previous therapies (1, 2, >2), previous new agents (bortezomib, thalidomide, both), time between first myeloma-specific therapy and lenalidomide plus dexametha- (Fig. 2c) . Based on the hazard ratio, we calculated a forest plot to illustrate the impact of the different parameters on TTP (Fig. 1a) . (Fig. 2b ). There was a trend towards shorter duration of survival (p=0.107) among patients with severe RI (CL Cr < 50 ml/min) when compared to patients with normal kidney function. This trend, however, was not significant. Patients who had received bortezomib or thalidomide prior to lenalidomide plus dexamethasone had a significant shorter duration of survival when compared to patients treated with schedules without new agents (p=0.018), with bortezomib (p=0.011) having a stronger influence than thalidomide (p= 0.103). In case both new agents were applied prior to lenalidomide plus dexamethasone, OS was negatively impacted (p<0.001) (Fig. 2d) . Similar results were observed when considering the number of previous treatment lines: patients with two (p=0.028) or more than two pre-treatment schemes (p<0.001) had a significant shorter duration of OS.
A detailed description is shown in Table 3 . Results are illustrated as forest plot as well (Fig. 1b) progressive disease during treatment with new agents, stem cell transplantation after lenalidomide plus dexamethasone therapy (time-dependent covariate), prior allogeneic transplantation and quality of response (≥PR). In multivariate analysis, the time between first myeloma-specific therapy and lenalidomide plus dexamethasone therapy (p=0.03) and the quality of response (p=0.02) were significant. Additionally, a propensity score analysis was performed to account for imbalances at baseline. The following baseline covariates are used to model the probability of having a severe renal impairment compared to having no renal impairment: age, sex, number of previous therapies, previous treatment with bortezomib, thalidomide or both, time between first MM treatment and start of lenalidomide plus dexamethasone, and time between last MM treatment and start of lenalidomide plus dexamethasone therapy (Fig. 3) .
Toxicity
Due to the retrospective nature of the study, complete toxicity data are not available for all patients. We therefore performed a subgroup analysis of 108 patients with available toxicity information referring to haematological toxicity, infectious complication and thromboembolic events. Patients with RI had a higher incidence of neutropenia than patients with normal kidney function (p=0.05). RI was also associated with a higher incidence of infections (p=0.03) especially with pneumonia (p=0.03). Thrombocytopenia was not significantly different. Anemia naturally occurred more frequently in the group of patients with renal impairment due to additional renal caused anemia. Thromboembolic events did not differ in the subgroups. The tolerance of therapy with lenalidomide plus dexamethasone was additionally measured by the frequency of dose reduction or discontinuation of therapy. These data are available for all patients. In 58 of 167 patients (34.7%), either therapy interruption or dose reduction was necessary. While patients with severe RI more often required interruption of treatment, for patients with moderate RI more frequently a dose reduction was performed (24.2 vs. 12.5% and 24.2 vs. 30.0%). In Fisher's exact test, the reduction of therapy reveals significance (p= 0.02) in case of RI, whereby in the testing for discontinuation of treatment, data do not reach significant levels (p=0.67). Further information on toxicity are shown in Tables 4 and 5 .
Alterations of renal impairment during lenalidomide plus dexamethasone treatment Among 167 patients, 152 were evaluable for follow-up CL Cr , of which 64 patients suffered from RI at baseline.
Principally, it needs to be considered that the pathogenesis of renal impairment remains unclear in the main proportion of patients. Beside myeloma-specific alterations, RI is also probably related to other myeloma-associated factors.
No alteration in the degree of renal impairment was seen in 123 of 152 patients (80.9%). When regarding patients with RI at the beginning of therapy, 17 of 64 (26.6%) showed an improvement of at least one level of the previously described subclasses. On the contrary, CL Cr had deteriorated in eight of 64 patients (12.5%). However, two of these eight patients had suffered from progressive disease at the time of deterioration of their renal function. We subsequently looked at the relationship between the improvement of renal function and the response to lenalidomide plus dexamethasone treatment. Patients who experienced an improvement or a stabilization of their kidney function noticeably obtained a higher frequency of at least a PR than patients who experienced a worsening of their renal function. Further information is displayed in Table 6 .
Discussion
Our data demonstrate that lenalidomide is highly active in relapsed and refractory MM patients. Even with impaired renal function or previous treatment schedules with new agents a remarkable ORR of about 62% and a CR rate of 11.4% can be reached. Nevertheless, response rates decreased with the extent of renal impairment from 67% to 48.5%. It needs to be taken into account that this is not mainly an effect of the severity of renal impairment but the impact of more prior therapies in the two groups with RI and a higher percentage of bortezomib containing regimes. This imbalance applies as well for TTP, which is significantly shortened in univariate analysis in cases of mild and ≥moderate RI. To account for these heterogeneities, we performed a multivariate analysis regarding TTP and OS. Multivariate analysis was only significant in patients with severe kidney dysfunction according the TTP. This finding is mainly caused by the significantly higher frequency of dose reduction in patients with RI due to more toxic side effects. Patients with RI had a higher incidence of neutropenia and infections. In particular, Fig. 3 Kaplan-Meier estimates for overall survival by renal impairment adjusted for additional covariates according to propensity score analysis the occurrence of pneumonia was more frequent than in patients with normal kidney function. Due to these adverse events, treatment schedules could not be realized as planned. Delay of treatment, dose reduction and interruption entailed not only the deterioration of response rates but also accounted for the shortened TTP. Rajkumar et al. demonstrated that the dose reduction of dexamethasone in the combination therapy with lenalidomide plus dexamethasone may result in a significantly worse ORR, but due of the reduction of toxic side effects and the necessity of less dose adjustments or dose interruptions a prolonged OS was obtained [20] . Recently, a dose adjustment protocol for patients with renal impairment was approved for use in the US and Europe. It suggested that lenalidomide 5 mg daily be used in patients requiring dialysis. This dosage has been chosen in order to decrease the fluctuation of lenalidomide plasma levels and the individual body load of each single dosage. This adjustment will most likely reduce toxic side effects and improve the compliance. Due to our single-centre experience, we reduced the dosage of dexamethasone per cycle about 50%, from 480 to 240 mg. A further reduction in analogy to the ECOG study to 160 mg might additionally reduce toxic side effects. A main goal in the treatment of MM patients with RI is the improvement of kidney function. Our data demonstrated that among the 152 evaluable patients 140 patients. (92.1%) had an unchanged renal status or an improvement of their renal impairment. Focussing on 64 patients with a CL Cr of 50 ml/min or less at baseline, 17 (26.6%) had an improvement in renal function. Patients who experienced an improvement or a stabilization of their kidney function noticeably obtained a higher frequency of at least a PR than patients who experienced a worsening of their renal function. The effect of disease control through the lenalidomide plus dexamethasone treatment seems to have a major impact on the course of renal function. Yet, it has to be borne in mind that for the main proportion of patients in our study population the pathogenesis of renal impairment remains unclear. Focussing on patients with proven solely myeloma associated renal dysfunction, would more likely result in an even higher percentage of renal function improvement.
As repeatedly mentioned, the efficacy of lenalidomide has a great relevance in the type, duration and sequence of previous myeloma-specific treatments. The effect of decreasing OS and TTP with each additional treatment line is a general feature for all kinds of myeloma-specific chemotherapy, reflecting the biology of the disease mainly by an increasing resistance feature of the plasma cell. FUO fever of unknown origin; DVT deep vein thrombosis; PE pulmonary embolism; RI renal insufficiency Recently published data from a subset analysis of two phase III studies with lenalidomide plus dexamethasone suggested the greatest benefit in terms of TTP in early use [17] . In our analysis, ORR diminished with increasing numbers of previous new agents from 64.3 to 52.9%. In relation to intensity and type of pre-treatment, OS in a univariate setting was significantly shortened after two and more previous treatments. The application of one of the two novel agents (thalidomide or bortezomib) resulted in a significant reduction of OS. While the use of thalidomide had no significant impact, previous therapy with bortezomib was significant. Applying both novel agents significantly decreased OS (p<0.001). In accordance to OS, the type of previous treatment schemes affected TTP. While the influence of thalidomide showed only a trend towards a shorter duration of TTP (p=0.067), the impact of bortezomib was highly significant (p=0.002). The application of both agents prior to lenalidomide was associated with a significant reduction of TTP (p<0.001). With regard to the mechanism of action, it cannot to be anticipated that the influence of the closely related drug thalidomide is less favourable in relation to response rate and TTP than previous therapy with bortezomib [31] . In our analysis, the use of thalidomide seemed to be partly negligible, with OS and TTP being significantly influenced by the previous application of bortezomib. The comparison of TTP and OS among different studies is limited because of varying inclusion and exclusion criteria. However, bortezomib seems to achieve a TTP duration of about 5 to 7 months in relapsed MM patients [25] [26] [27] . Data on the efficacy and safety of bortezomib in patients with RI from the sub-analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) study revealed that TTP was less than 4.9 months for patients with CL Cr <50 ml/min and 6.2 months for patients with moderate RI [24] . Comparable patient characteristics with one to three previous therapies can be found in an other phase III study which investigated the use of pegylated liposomal doxorubicin plus bortezomib vs. bortezomib alone with 199 days for the bortezomib mono group and 190 days among patients with normal kidney function [28] . In the phase II Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma (CREST) study, two doses of bortezomib alone or in combination with dexamethasone were evaluated as second-line therapy in MM. With the addition of dexamethasone, the 1.3 mg/m² cohort achieved a TTP of 11 months [29] . Patient characteristics that correlate better to our heavily pretreated cohort can be found in the phase II study in which 202 patients were enrolled. These mainly refractory patients reached an ORR (≥PR) of 27% and a median TTP of 7 months [30] . Compared to the above-mentioned studies, the duration of response is noticeably longer for patients receiving lenalidomide plus dexamethasone than bortezomib monotherapy. The TTP among patients with severe RI (6.0 months) in our study group is nearly as long as that for patients without renal disorder who are treated with bortezomib in the APEX study (6.3 months) or in the phase III study which investigated the use of pegylated liposomal doxorubicin plus bortezomib [28] .
Considering that our investigated cohort was heavily pretreated, a median OS of 25.8 months is considerable. Although our data indicate a trend towards a shorter OS in patients with severe renal impairment compared to those with normal renal function, the findings were not significant. Additionally, a propensity score analysis was performed to account for imbalances at baseline, mainly the differences in the kind and intensity of previous therapies (Fig. 3) . The approach of the curves is obvious and reflects the sequence of events. We demonstrate that OS is not significantly shortened in patients with severe RI.
In conclusion, our data endorse the potency of this immunomodulatory drug even in heavily pre-treated MM patients with various degrees of renal impairment. This analysis substantiates previous data that the effectiveness is higher in its early use. However, the most favourable sequence of various new agents cannot be deducted from our data. At this point, we want to elude the limitations of our study due to its retrospective nature. Nevertheless, this study population reflects the daily routine of hematologists in a university hospital. However, prospective trials are needed to answer the question on how to effectively sequence myeloma-specific therapy regimens. Considering the ongoing discussion of effective initial therapy with a combination of different kinds of new agents, the strategy of salvage therapy should be reconsidered as well. Lenalidomide is able to induce the longest TTP in relapsed and refractory MM patients compared to other standardized conventional myeloma therapies and achieves even in heavily pre-treated patients an improvement of renal function in a significant number of patients (25-30%). Side effects need to be recognized but are manageable for versed hematologists and oncologists. The new medication schedule for patients with moderate and severe renal impairment will in all likelihood reduce the problems of adverse effects, dose reduction and treatment interruption. There is no reason to generally avoid or shift the potent treatment option with lenalidomide for patients with RI at a later time.
